Improve Parkinson detection and tracking
- Trial ID
- NCT05370079
- Official Title
- Control Cohort CTRL COH
- Goal
- Improve Parkinson detection and tracking
- Phase
- NA
- Status
- RECRUITING
- Sponsor
- Hospices Civils de Lyon
- Study Type
- INTERVENTIONAL
- Enrollment
- 350 participants
- Conditions
- Parkinson's Disease; Amyotrophic Lateral Sclerosis; Glioblastoma; Cancer Without Neurological Disease; Rheumatoid Polyarthritis
- Interventions
- Collection of biological sample (blood and/or CSF)
Plain-Language Summary
The goal is to build a control cohort of blood and spinal fluid samples so researchers can identify and compare biomarkers tied to Parkinson's and other conditions, helping future studies detect, track, or tell diseases apart. Participants give blood and sometimes cerebrospinal fluid, which scientists analyze for proteins, immune markers, and other signals, and the visit does not test a drug or change your medications like levodopa. Adults 18 and older with Parkinson's, ALS, glioblastoma, certain non‑neurological cancers, or rheumatoid arthritis who can give consent may join, while people with paraneoplastic neurological syndromes or autoimmune encephalitis and those under guardianship are excluded; about 350 participants are planned.
Locations
- Hospices Civils de Lyon, Bron, France
Frequently Asked Questions
- What is this trial testing?
- This trial is studying Collection of biological sample (blood and/or CSF). The goal is to build a control cohort of blood and spinal fluid samples so researchers can identify and compare biomarkers tied to Parkinson's and other conditions, helping future studies detect, track, or tell diseases apart. Participants give blood and sometimes cerebrospinal fluid, which scientists analyze for proteins, immune markers, and other signals, and the visit does not test a drug or change your medications like levodopa. Adults 18 and older with Parkinson's, ALS, glioblastoma, certain non‑neurological cancers, or rheumatoid arthritis who can give consent may join, while people with paraneoplastic neurological syndromes or autoimmune encephalitis and those under guardianship are excluded; about 350 participants are planned.
- Who can participate?
- Participants must be at least 18 Years.
- Where is this trial located?
- This trial is recruiting at 1 location.
- Does it cost anything to join?
- No. There is no cost to participate. Study-related care and treatment are provided at no charge.
- How long does the trial last?
- This trial is estimated to last approximately 5 years.